Alithea Bio

The Company in Brief

Alithea Bio, formally Alithea Biotechnology GmbH, is a biotechnology company headquartered in Freiburg, Germany. Founded in 2019, the company focuses on HLA immunopeptidomics to advance T-cell mediated cancer treatments by characterizing peptides presented by HLA molecules [Crunchbase].

The founding team includes Fanny Giannou, CEO, and Tim Fugmann, Chief Scientific Officer and co-founder [Crunchbase, Bruker]. Giannou brings a business development background, while Fugmann holds a PhD from ETH Zürich and specializes in HLA peptidomics [Crunchbase, LinkedIn - Tim Fugmann]. The company has participated in the BadenCampus accelerator, the Zentrales Innovationsprogramm Mittelstand (ZIM), and the Women TechEU award in 2024 [LinkedIn - Fanny Giannou]. Alithea Bio reports the completion of its first commercial contracts [Alithea Bio about-us].

Data Accuracy: YELLOW -- Founding year and entity name corroborated by Crunchbase; team roles and accelerator participation cited from LinkedIn and company materials. Key milestone (first contracts) is a company-only claim.

What They Have Built

Alithea Bio's commercial offering centers on a software platform for analyzing HLA-presented peptides. The core product, HLA-Compass, is a bioinformatics pipeline for characterizing these peptides with quality control and mapping to specific HLA alleles [Alithea Bio]. A companion tool, NeoZOOM, is listed for predicting off-target toxicity [Alithea Bio]. The technology stack integrates immunopeptidomics, proteogenomics, and applied AI [Alithea Bio].

The platform's differentiation is anchored in a proprietary dataset. Co-founder Tim Fugmann has cited an HLA peptide database compiled from 3,000 samples, covering 1.1 million ligands with abundance data [PMWC]. The company also claims a validated proteogenomics pipeline for neoantigen discovery from patient tumor samples [Alithea Bio].

Data Accuracy: YELLOW -- Product claims are sourced from the company website; the database size is cited in a third-party speaker bio but not independently verified. Commercial contract claims are company-only.

Market Size and Demand

Commercial momentum for neoantigen discovery platforms is driven by clinical validation, immunotherapy adoption, and the need to improve therapeutic safety. The global neoantigen discovery platform market was valued at approximately $1,200M in 2023, with projections to reach $3,500M by 2030 [Grand View Research, 2023]. The broader cancer immunotherapy market was estimated at $116,000M in 2023 [Precedence Research, 2024].

Metric	Value
Neoantigen Discovery Platforms (2023)	$1,200M
Cancer Immunotherapy Market (2023)	$116,000M

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous segments; specific immunopeptidomics platform TAM is not confirmed.

Who Else Is Fighting for This

Alithea Bio operates in a niche where primary competition includes internal pharma R&D teams, proteomics CROs, bioinformatics software vendors, and academic consortia like the Immune Epitope Database (IEDB) [Alithea Bio, Bruker, PMWC]. The company's edge is its claimed proprietary database of 1.1 million ligands from 3,000 samples [PMWC].

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated market position and broader industry structure; no direct competitor names are publicly cited.

Opportunity

Alithea Bio aims to become a foundational data and analytics layer for precision immunotherapy. The company's tools address the bottleneck of predicting tumor-specific peptides and off-target toxicity [Alithea Bio].

Data Accuracy: YELLOW -- Opportunity framing is extrapolated from company-stated mission and product claims; database scale claim is from a speaker bio but not independently verified.

Sources

1. [Alithea Bio] Alithea bio | https://alithea-bio.com/
2. [Alithea Bio] About Us - Alithea Biotechnology GmbH | https://alithea-bio.com/about-us/
3. [Crunchbase] Alithea Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/alithea-bio
4. [LinkedIn - Fanny Giannou] Fanny Giannou - Berlin, Berlin, Germany | Professional Profile | LinkedIn | https://www.linkedin.com/in/fanny-giannou-352416225/
5. [PMWC] Tim Fugmann - 2023sv - PMWC Precision Medicine World Conference | https://www.pmwcintl.com/speaker/tim-fugmann-478_alithea-bio-ug_2023sv
6. [Bruker] Unlocking the full potential of immunopeptidomics with the timsTOF Ultra | Bruker | https://www.bruker.com/en/news-and-events/webinars/2024/unlocking-the-full-potential-of-immunopeptidomics-with-the-timstof-ultra.html
7. [LinkedIn - Tim Fugmann] Tim Fugmann - Alithea Bio UG | LinkedIn | https://www.linkedin.com/in/tim-fugmann-a1639914/
8. [Grand View Research, 2023] Neoantigen Discovery Platform Market Size, Share & Trends Analysis Report | Grand View Research | https://www.grandviewresearch.com/industry-analysis/neoantigen-discovery-platform-market-report
9. [Precedence Research, 2024] Cancer Immunotherapy Market Size, Growth, Trends | Precedence Research | https://www.precedenceresearch.com/cancer-immunotherapy-market